BOSTON — Greater Boston’s life sciences real estate market may be entering a new phase of stabilization after several years of correction, according to a new JLL U.S. Lab Property Report. The national analysis also points to early signs of recovery across major U.S. life sciences hubs, even as conditions remain uneven between top-tier and secondary markets.
In Metro Boston, lab availability remains elevated at 33.3%, among the highest in the country. However, the report notes a meaningful shift in momentum: total available lab space declined 2.1% year-over-year, suggesting the market may be beginning to absorb excess inventory accumulated during the recent development cycle.
JLL characterizes this as a potential inflection point, with improving demand and tightening availability signaling the early stages of rebalancing in one of the nation’s most closely watched innovation markets.
Boston Demand Stabilizing Within Long-Term Innovation Cycle
Despite recent volatility, Boston continues to anchor the U.S. life sciences sector as part of the “big three” markets alongside the Bay Area and San Diego.
These three hubs have collectively averaged approximately 75 lab deals per quarter over the past two years—about 35% above pre-pandemic levels—underscoring a structurally stronger baseline of demand even after the post-2021 correction.
“The market looks very different than it did in 2021, but leasing activity suggests a stronger long-term foundation than many expected during the downturn,” the report notes.
Demand Concentrated in Core Innovation Hubs
Across the top four U.S. markets—Boston, San Diego, the Bay Area, and Raleigh-Durham—demand has rebounded sharply, rising roughly 44% since early 2025 to nearly 7.9 million square feet.
In contrast, secondary markets continue to lag, with demand declining by approximately 3 million square feet over the past three years while available space has expanded by 4.4 million square feet.
JLL attributes the divergence to stronger capital flows, more robust biotech financing conditions, and increased M&A activity concentrated in leading innovation clusters.
Flight to Quality Reshapes Boston Leasing Dynamics
A defining trend in Boston’s market is the continued “flight to quality,” with tenants increasingly favoring newer, highly amenitized lab buildings over older assets—even in well-located submarkets.
Buildings delivered since 2020 have seen availability fall by roughly 6 percentage points over the past year, driven by more than 2.6 million square feet of absorption. Older properties, by contrast, continue to face upward pressure on vacancy.
“The great reshuffling is underway,” the report notes, as tenants prioritize operational efficiency, modern infrastructure, and access to talent over purely location-driven decisions.
Oversupply Continues to Shape Tenant-Favorable Conditions
Despite improving fundamentals, elevated supply continues to define the market environment. Across Boston and other major hubs, landlords are competing aggressively for tenants, leading to shorter lease terms, higher concessions, and declining asking rents.
For smaller direct leases, average terms have fallen to approximately 62 months—down 20% from pre-pandemic levels—while asking rents across the sector have declined roughly 18% since 2023.
Emerging Demand From “Tough Tech” Users
Another structural shift is the growing presence of non-traditional life sciences tenants in Boston’s lab market. In 2025, approximately 30% of lab leases in the region were driven by “alternative users,” including companies in artificial intelligence, robotics, medtech, aerospace, and defense—triple the share recorded four years earlier.
These “tough tech” firms are increasingly seeking dry lab and prototyping environments, further blurring the lines between traditional life sciences and advanced technology sectors.
National Market Highlights
While Boston remains a key focal point, the report identifies several broader U.S. trends shaping the life sciences sector:
Availability is beginning to contract nationally
U.S. lab availability has started to decline after years of expansion, with roughly 2 million square feet of net absorption recorded over the past nine months.
Big three markets set the tone for recovery
Boston, San Diego, and the Bay Area continue to lead national activity, averaging ~75 deals per quarter—well above pre-pandemic norms and establishing a new baseline for leasing activity.
Demand is increasingly polarized geographically
Top-tier markets are driving nearly all recent growth, while secondary markets continue to see falling demand and rising availability.
A sustained flight to quality is reshaping leasing
Newer lab buildings are capturing the majority of tenant demand, while older assets face increasing vacancy pressure.
Leasing conditions remain highly tenant-favorable
Across the U.S., lease terms are shortening, concessions are rising, and asking rents have declined approximately 18% since 2023 due to persistent oversupply.
Dry lab and “tough tech” users are expanding nationally
AI, robotics, medtech, aerospace, and defense companies are increasingly occupying lab R&D space, especially in innovation hubs like Boston and the Bay Area, reflecting the convergence of physical and digital innovation.
The report suggests the U.S. life sciences real estate market is gradually transitioning from a correction phase toward stabilization. While elevated vacancy and competitive leasing conditions persist, improving demand fundamentals and a more diversified tenant base are signaling the early stages of a longer-term recovery cycle.
For Greater Boston, the data points to a market still working through excess supply—but one that may be nearing a turning point within a broader national rebound.
